Gabriel Ohana Marques Azzini1, Gabriel Silva Santos2, Silvia Beatriz Coutinho Visoni3, Vitor Ohana Marques Azzini1, Rafael Gonzales Dos Santos1, Stephany Cares Huber4, José Fábio Lana1. 1. Orthopedics, Sports Medicine, Pain Physician, IOC, Instituto do Osso e da Cartilagem, The Bone and Cartilage Institute, Presidente Kennedy Avenue, 1386, 2nd Floor, Room #29, Cidade Nova I, Indaiatuba, SP, Brazil. 2. Biomedical Scientist, IOC, Instituto do Osso e da Cartilagem, The Bone and Cartilage Institute, Presidente Kennedy Avenue, 1386, 2nd Floor, Room #29, Cidade Nova I, Indaiatuba, SP, Brazil. 3. Biologist, IOC, Instituto do Osso e da Cartilagem, The Bone and Cartilage Institute, Presidente Kennedy Avenue, 1386, 2nd Floor, Room #29, Cidade Nova I, Indaiatuba, SP, Brazil. 4. Biomedical Scientist, Universidade Estadual de Campinas (UNICAMP), The University of Campinas, Cidade Universitária Zeferino Vaz, Campinas, SP, Brazil.
Abstract
Metabolic syndrome (MS) has become one of the top major health burdens for over three decades not only due to its effects on cardiovascular health but also its implications in orthopedics. Extensive research has shown that MS is tightly linked to osteoarthritis and inflammation, a process which appears to primarily occur in the subchondral bone via the incidence of bone-marrow lesions (BMLs). Numerous studies identify obesity, dyslipidemia, insulin resistance and hypertension as the top metabolic risk factors, the so-called "deadly quartet". These factors are responsible for the disruptive physiological processes that culminate in detrimental alterations within the subchondral bone, cartilage damage and, overall, the predominant pro-inflammatory joint microenvironment. Although it has long been thought that osteoarthritis was limited to the cartilage component of the joint, other studies indicate that the disease may originate from the harmful alterations that occur primarily in the subchondral bone, especially via means of vascular pathology. Since metabolic risk factors are manageable to a certain extent, it is therefore possible to decelerate the progression of OA and mitigate its devastating effects on the subchondral bone and subsequent articular cartilage damage. METHODS: Literature was reviewed using PubMed and Google Scholar in order to find a correlation between metabolic syndrome and osteoarthritic progression. The investigation included a combination of nomenclature such as: "metabolic syndrome", "obesity", "insulin resistance", "hypertension", "dyslipidemia", "low-grade systemic inflammation", "osteoarthritis", "subchondral bone", "cartilage" and "inflammatory biomarkers". CONCLUSION: Based on several studies, there seems to be a significant association between The Deadly Quartet (metabolic syndrome), dysregulation of both pro- and anti-inflammatory biomarkers, and osteoarthritic progression arising from unbridled systemic inflammation.
Metabolic syndrome (MS) has become one of the top major health burdens for over three decades not only due to its effects on cardiovascular health but also its implications in orthopedics. Extensive research has shown that MS is tightly linked to osteoarthritis and inflammation, a process which appears to primarily occur in the subchondral bone via the incidence of bone-marrow lesions (BMLs). Numerous studies identify obesity, dyslipidemia, insulin resistance and hypertension as the top metabolic risk factors, the so-called "deadly quartet". These factors are responsible for the disruptive physiological processes that culminate in detrimental alterations within the subchondral bone, cartilage damage and, overall, the predominant pro-inflammatory joint microenvironment. Although it has long been thought that osteoarthritis was limited to the cartilage component of the joint, other studies indicate that the disease may originate from the harmful alterations that occur primarily in the subchondral bone, especially via means of vascular pathology. Since metabolic risk factors are manageable to a certain extent, it is therefore possible to decelerate the progression of OA and mitigate its devastating effects on the subchondral bone and subsequent articular cartilage damage. METHODS: Literature was reviewed using PubMed and Google Scholar in order to find a correlation between metabolic syndrome and osteoarthritic progression. The investigation included a combination of nomenclature such as: "metabolic syndrome", "obesity", "insulin resistance", "hypertension", "dyslipidemia", "low-grade systemic inflammation", "osteoarthritis", "subchondral bone", "cartilage" and "inflammatory biomarkers". CONCLUSION: Based on several studies, there seems to be a significant association between The Deadly Quartet (metabolic syndrome), dysregulation of both pro- and anti-inflammatory biomarkers, and osteoarthritic progression arising from unbridled systemic inflammation.
Authors: David T Felson; Jingbo Niu; Ali Guermazi; Frank Roemer; Piran Aliabadi; Margaret Clancy; James Torner; C Elizabeth Lewis; Michael C Nevitt Journal: Arthritis Rheum Date: 2007-09
Authors: David J Hunter; Yuqing Zhang; Jingbo Niu; Joyce Goggins; Shreyasee Amin; Michael P LaValley; Ali Guermazi; Harry Genant; Daniel Gale; David T Felson Journal: Arthritis Rheum Date: 2006-05
Authors: F Viazzi; D Garneri; G Leoncini; A Gonnella; M L Muiesan; E Ambrosioni; F V Costa; G Leonetti; A C Pessina; B Trimarco; M Volpe; E Agabiti Rosei; G Deferrari; R Pontremoli Journal: Nutr Metab Cardiovasc Dis Date: 2014-02-08 Impact factor: 4.222
Authors: C Sanchez; M A Deberg; N Piccardi; P Msika; J-Y L Reginster; Y E Henrotin Journal: Osteoarthritis Cartilage Date: 2005-09-13 Impact factor: 6.576
Authors: Aimee Landar; Jaroslaw W Zmijewski; Dale A Dickinson; Claire Le Goffe; Michelle S Johnson; Ginger L Milne; Giuseppe Zanoni; Giovanni Vidari; Jason D Morrow; Victor M Darley-Usmar Journal: Am J Physiol Heart Circ Physiol Date: 2005-12-30 Impact factor: 4.733
Authors: Y Karter; S Aydin; A Curgunlu; H Uzun; N Ertürk; S Vehid; A Kutlu; G Simsek; R Yücel; A Arat; E Ozturk; S Erdine Journal: J Hum Hypertens Date: 2004-11 Impact factor: 3.012
Authors: José Fábio Santos Duarte Lana; Anna Vitória Santos Duarte Lana; Lucas Furtado da Fonseca; Marcelo Amaral Coelho; Guilherme Gabriel Marques; Tomas Mosaner; Lucas Leite Ribeiro; Gabriel Ohana Marques Azzini; Gabriel Silva Santos; Eduardo Fonseca; Marco Antonio Percope de Andrade Journal: J Stem Cells Regen Med Date: 2022-04-05
Authors: Marcelo Amaral Coelho; Madhan Jeyaraman; Naveen Jeyaraman; Ramya Lakshmi Rajendran; André Atsushi Sugano; Tomas Mosaner; Gabriel Silva Santos; João Vitor Bizinotto Lana; Anna Vitória Santos Duarte Lana; Lucas Furtado da Fonseca; Rafael Barnabé Domingues; Prakash Gangadaran; Byeong-Cheol Ahn; José Fábio Santos Duarte Lana Journal: Bioengineering (Basel) Date: 2022-05-18
Authors: Luciano C Ramires; Gabriel Silva Santos; Rafaela Pereira Ramires; Lucas Furtado da Fonseca; Madhan Jeyaraman; Sathish Muthu; Anna Vitória Lana; Gabriel Azzini; Curtis Scott Smith; José Fábio Lana Journal: Int J Mol Sci Date: 2022-01-27 Impact factor: 5.923